Clinical outcomes of stage I endometrial carcinoma patients treated with surgery alone: Siriraj Hospital experiences

Suwanit Therasakvichya,1 Sompop Kuljarusnont,1 Janjira Petsuksiri,2 Pattama Chaopotong,1 Vuthinun Achariyapota,1 Pisutt Srichaikul,1 Atthapon Jaishuen1

1Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
2Division of Radiation Oncology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

ABSTRACT

Objective: To evaluate the recurrence rates and patterns of failure in patients with stage I endometrial carcinoma after surgical staging without adjuvant therapy.

Methods: Medical records of 229 patients with stage I endometrial carcinoma, treated with surgery alone between 2002 and 2010 at Siriraj Hospital were retrospectively reviewed. The primary objective of this study was recurrence rates. The secondary objectives were patterns of failure, disease-free survival, overall survival, and prognostic factors related to outcomes.

Results: During median follow-up time of 53.3 months, 11 recurrences (4.8%) occurred with a median time to recurrence of 21.2 months (range, 7.7 to 77.8 months). Vaginal recurrence was the most common pattern of failure (8/11 patients, 72.7%). Other recurrences were pelvic, abdominal and multiple metastases. Factors that appeared to be prognostic factors on univariate analyses were age and having high intermediate risk (HIR) (Gynecologic Oncology Group [GOG] 99 criteria), none of which showed significance in multivariate analysis. The recurrence rates were higher in the patients with HIR criteria (22.2% vs. 4.1%, p=0.013) or patients with stage IB, grade 2 endometrioid carcinoma (9.4% vs. 4.3%, p=0.199). Five-year disease-free survival and 5-year overall survival were 93.9% (95% CI, 89.9 to 95.86) and 99.5% (95% CI, 97.0 to 99.9), respectively.

Conclusion: The patients with low risk stage I endometrial carcinoma had excellent outcomes with surgery alone. Our study showed that no single factor was demonstrated to be an independent predictor for recurrence.

Keywords: Endometrial Neoplasms; Stage I; Surgery

INTRODUCTION

Endometrial cancer is the most common gynecologic malignancy in the developed countries including the United States [1]. It is estimated that 47,100 new endometrial cancer cases occur in 2012, with 8,000 deaths resulting from the disease [2]. The incidence is lower in the developing countries, however it becomes increasingly important [3]. In 2007 to 2009, its incidence was 2 to 4 per 100,000 of Thai females [4].
Surgery is the mainstay of treatment, consists of total hysterectomy with bilateral salpingo-oophorectomy (TH-BSO) [5]. The role of pelvic and para-aortic lymph node sampling or lymphadenectomy is still debatable [6-8]. After surgery, patients are divided into three risk groups of recurrences (low, intermediate, and high), based on multiple factors, including patients’ age, histologic subtype, tumor grade, staging of disease and presence of lymphovascular space invasion [9-13].

Low risk endometrial cancer (International Federation of Gynecology and Obstetrics [FIGO] 1988, stage IA–IB grade 1, and stage IA grade 2) has a minimal risk for pelvic lymph node metastasis (≤5%) [14] or vaginal recurrence (0.4% to 3.1%), with high disease-free survival (DFS) rate (95%) [15]. It is generally accepted that low-risk, stage I patients do not benefit from adjuvant treatment [15,16].

The purpose of this study was to evaluate the treatment outcomes and patterns of recurrence in stage I patients who were surgically treated without adjuvant treatment. Clinical and pathological factors were evaluated for prognostic significance. The results will potentially facilitate the selection of patients who may benefit from adjuvant treatment, and adjust the standard of care.

MATERIALS AND METHODS

After receiving an approval by the Institutional Review Board of the Faculty of Medicine Siriraj Hospital, a retrospective review of medical records was performed in 229 patients with stage I endometrial cancer, who were treated with surgery alone between 2002 and 2010. The primary outcome of this study was to identify the recurrence rate in surgically managed stage I endometrial cancer patients. The secondary outcomes were to explore the failure patterns, DFS, overall survival (OS), and prognostic factors relating to the survival.

The inclusion criteria were stage I endometrial cancer (FIGO 1988) [5], who underwent standard surgical treatment with at least removal of the uterus and adnexal structures (TH-BSO) with no adjuvant postoperative radiation therapy (PORT) or chemotherapy. As our study was retrospectively review, FIGO 1988 staging system was used during that period of time for treatment selection. Therefore we used the FIGO 1988 system for data analyses. Also, the recent rationale for treatment recommendation was generally based on the details of the FIGO 1988 system. We excluded the patients who had insufficient follow-up data or patients who were diagnosed with other malignancies within 5 years prior to endometrial cancer diagnosis.

All pathologies were centrally reviewed. Histologic subtypes were determined according to World Health Organization (WHO) classification [17]. All of patients’ information were reviewed. The follow-up visits were scheduled every 3 to 4 months during the first 2 years, every 6 months to 5 years, then annually. During the follow-up evaluation, data regarding medical history and pelvic examination were obtained. Vaginal recurrence was confirmed by tissue biopsy and pathology. Regional and distant recurrences were diagnosed by physical examinations and imaging studies. Computed tomography (CT)/magnetic resonance imaging (MRI) scan of abdomen was not performed routinely, unless patients developed clinically suspicious recurrent diseases.
For sample size calculation, we used 5% of any recurrences after treating with surgery alone [18]. Calculation of the sample size with acceptable tolerance at 3% and confidence level at 0.95, required a sample size of 203 cases (using a nQuery program, Statistical Solutions Ltd., Ireland) with 10% sparing due to incomplete data in retrospective study. The total of at least 223 patients were recruited in this study. Descriptive data were described with median, mean and standard deviation. Chi-square tests were performed to compare categorical variables. Cox regression method was used in univariate and multivariate analyses. Survival analyses were performed with Kaplan-Meier curve.

RESULTS

From 2002 to 2010, 229 patients with stage I endometrial cancer treated with surgery alone were included. We excluded two patients who had insufficient data, leaving 227 patients for analysis. Of these 227 patients, 180 patients (79.3%) underwent TH-BSO and pelvic lymph nodes removal; the remaining 47 patients (20.7%) underwent hysterectomy without surgical evaluation of lymph nodes by different reasons (morbid obesity, severe medical comorbidities, discretion of the operators). Para-aortic lymph node evaluation was performed in 37% (84/227 patients) of patients. Most of cases underwent para-aortic lymph node sampling up to the level of inferior mesenteric artery. Only four cases were dissected to the level of renal vessels. The most common pathology was endometrioid carcinoma (97.8%). Patients’ characteristics, clinicopathological features were demonstrated in Table 1.

During median follow-up of 53.3 months (range, 0.2 to 120.7 months), 11 recurrences (4.8%) occurred with a median time to recurrence of 21.2 months (range, 7.7 to 77.8 months). Most common pattern of recurrence was vaginal recurrence (72.7%, 8/11 patients). Other recurrences were pelvic failure (one patient), abdominal failure (one patient), and multiple metastases (one patient). Table 2 demonstrates the distribution of patients with recurrence according to each stage and grade. The recurrence rate was 4.3% (8/186 patients) in low risk group (FIGO 1988 stage IA, grade 1–2 and stage IB, grade 1). Remarkably, the recurrence rate was higher in the patients with patients with high intermediate risk (HIR) based on Gynecologic Oncology Group (GOG) 99 criteria (22.2% vs. 4.1%, p=0.013) [12]. Also, patients with stage IB, grade 2 showed a trend to have higher recurrence than those with lower stage or grade (9.4% vs. 4.3%, p=0.199). Median number of pelvic lymph nodes harvested was 12. Number of pelvic lymph nodes harvested did not significantly affect recurrence (1.1% vs. 7.6% for >12 nodes vs. <12 nodes, p=0.080). FIGO 1988 stage IA was not different from stage IB to predict recurrence (stage IA 5.3% vs. stage IB 4.7%, p=0.786).

Most of the patients (8 out of 11 patients) received salvage radiation therapy, with median OS of 53.3 months (range, 14.9 to 105.3 months) after recurrence. In overall, 5-year DFS and 5-year OS for the whole group were 93.9% (95% CI, 89.9 to 93.86) and 99.5% (95% CI, 97.0 to 99.9), respectively (Figs. 1, 2).

In univariate analysis, older age (>70 years old) and having HIR according to the GOG 99 criteria [12] appeared to be prognostic factors to predict recurrence. There was no independent predicting factor for recurrence on multivariate analysis (Table 3).
DISCUSSION

To our knowledge, this is the largest report of stage I endometrial cancer treated with surgery in Thailand. Most of patients in our study underwent TH-BSO with pelvic lymph nodes removal, although 20.4% of the patients underwent only TH-BSO. The primary treatment of endometrial cancer is surgery, consists of at least TH-BSO. The role of systematic lymphadenectomy is controversial. The former studies reported no benefit of

---

Table 1. Patients' characteristics, staging, pathology, and treatment

| Characteristic                  | Value               |
|--------------------------------|---------------------|
| Total no. of patients          | 227                 |
| Age (yr)                       | 55 (28-82)          |
| ≤70                            | 209 (92.1)          |
| >70                            | 18 (7.9)            |
| Body mass index (kg/m²)        | 25.8 (15.2-49.8)    |
| ≤30                            | 178 (78.4)          |
| >30                            | 49 (21.6)           |
| Pelvic lymph node harvested (node) | 12 (0-72)       |
| ≤12                            | 92 (51.1)           |
| >12                            | 88 (48.9)           |
| Histology                      |                     |
| Endometrioid                   | 222 (97.8)          |
| Non-endometrioid               | 5 (2.2)             |
| Histologic grade               |                     |
| 1                              | 174 (76.7)          |
| 2                              | 47 (20.7)           |
| 3                              | 6 (2.6)             |
| Tumor size (cm)                |                     |
| ≤2                             | 108 (47.6)          |
| >2                             | 119 (52.4)          |
| Myometrial Invasion (%)        |                     |
| No                             | 95 (41.9)           |
| ≤50                            | 129 (56.8)          |
| >50                            | 3 (1.3)             |
| Lower uterine segment involvement |                     |
| Absent                         | 187 (82.4)          |
| Present                        | 40 (17.6)           |
| Lymphovascular space invasion (LVSI) |             |
| Absent                         | 219 (94.5)          |
| Present                        | 8 (3.5)             |
| FIGO 1988 stage                |                     |
| IA                             | 95 (41.9)           |
| IB                             | 129 (56.8)          |
| IC                             | 3 (1.3)             |

Values are presented as median (range) or number (%). FIGO, International Federation of Gynecology and Obstetrics.

Table 2. Recurrence rates by stage and grade

| FIGO 1988 stage | Grade 1 (n=174) | Grade 2 (n=47) | Grade 3 (n=6) |
|-----------------|-----------------|----------------|---------------|
| IA (n=95)       |                 |                |               |
| Total           | 77              | 14             | 4             |
| Recurrence      | 4 (5.2)         | 1 (7.1)        | 0             |
| IB (n=129)      |                 |                |               |
| Total           | 95              | 32             | 2             |
| Recurrence      | 3 (3.2)         | 3 (9.4)        | 0             |
| IC (n=3)        |                 |                |               |
| Total           | 2               | 1              | 0             |
| Recurrence      | 0               | 0              | 0             |

Values are presented as number (%). FIGO, International Federation of Gynecology and Obstetrics.
lymphadenectomy in terms of either OS or recurrence-free survival in patients with early stage endometrial cancer [6,7,13,19]. However, the results have been criticized due to the potential bias from adjuvant radiotherapy (RT) [8]. Our study confirmed no significant correlation between number of pelvic lymph nodes harvested and recurrence in patients with early stage disease who underwent surgery alone. This was in accordance with our institute's prior study, which showed no benefit of extensive lymphadenectomy for endometrial cancer patients who received adjuvant RT [20]. In the present study, pelvic/para-aortic lymph nodes evaluation and the level of para-aortic lymph node evaluation were dependent on the operator and the feasibility of the procedures. Four cases that underwent para-aortic lymph

![Fig. 1. Five-year disease-free survival.](http://ejgo.org)

![Fig. 2. Five-year overall survival.](http://ejgo.org)
nodes evaluation up to the level of renal vessels had body mass index (BMI) less than 25 kg/m². None of five patients with BMI more than 40 kg/m² underwent either pelvic or para-aortic lymph node evaluation.

Patients with grade 1 and 2 endometrioid carcinoma confined to the endometrium are considered as low risk with 2% to 4% recurrence rate [21-23]. Our study reported 4.3% recurrence rate in low risk patients (FIGO 1988 stage IA, grade 1–2 and stage IB, grade 1) within the same range of other studies. This group of patients demonstrated an excellent prognosis after comprehensive surgical staging. No study of adjuvant treatment has shown survival benefit in low risk group patients [11,12]. Thus, postoperative therapy is usually withheld [15,23,24]. Our study showed that patients with age of >70 years or having high-intermediate risk criteria (according to GOG 99 [12]) are potentially at increased risk of recurrence.

PORT is typically recommended in patients with intermediate risk, aiming to reduce locoregional recurrence from 6.9% to 14% down to 1.6% to 5% at 2 to 10 years [10,12,25]. Our study demonstrated 9.4% recurrence rate among patients with stage IB, grade 2 diseases. This result confirmed that this group of patients should be recommended to receive PORT. The prior study from our institute showed no recurrence in low intermediate risk patients (FIGO 1988 stage IA grade 3, IB grade 2) who received adjuvant radiation therapy [20].

### Table 3. Univariate and multivariate analyses of prognostic factors for recurrence

| Prognostic factor                      | Total (n=227) | No. of recurrence | Univariate for recurrence | Multivariate for recurrence |
|----------------------------------------|---------------|-------------------|---------------------------|-----------------------------|
|                                        |               |                   | HR (95% CI) | p-value | HR (95% CI) | p-value |
| Age (yr)                               |               |                   |              |         |              |         |
| ≤70                                    | 209           | 8                 | 1.0          | 0.045   | 1.0          | 0.435   |
| >70                                    | 18            | 3                 | 10.14 (1.05-97.64) | 2.95 (0.19-44.86) |
| Body mass index (kg/m²)                |               |                   |              |         |              |         |
| <30                                    | 178           | 6                 | 1.0          | 0.074   | 1.0          | 0.256   |
| ≥30                                    | 49            | 5                 | 2.96 (0.90-9.37) | 2.34 (0.54-10.13) |
| FIGO 1988 stage                        |               |                   |              |         |              |         |
| IA                                     | 95            | 5                 | 1.0          | -       | -            | -       |
| IB                                     | 129           | 6                 | 0.85 (0.26-2.79) | -       | -            | -       |
| PLN harvested (node)                   |               |                   |              |         |              |         |
| ≥12                                    | 180           | 1                 | 1.0          | 0.082   | 1.0          | 0.118   |
| <12                                    | 88            | 1                 | -            | -       | -            | -       |
| Histologic grade                       |               |                   |              |         |              |         |
| 1                                      | 174           | 7                 | 1.0          | 0.253   | 1.0          | -       |
| 2-3                                    | 53            | 4                 | 2.05 (0.60-7.00) | -       | -            | -       |
| Tumor size (cm)                        |               |                   |              |         |              |         |
| ≤2                                     | 108           | 5                 | 1.0          | 0.875   | 1.0          | -       |
| >2                                     | 119           | 6                 | 1.10 (0.34-3.61) | -       | -            | -       |
| Lower uterine segment involvement      |               |                   |              |         |              |         |
| Absent                                 | 187           | 9                 | 1.0          | 0.995   | 1.0          | -       |
| Present                                | 40            | 2                 | 1.00 (0.22-4.61) | -       | -            | -       |
| LVI                                    |               |                   |              |         |              |         |
| Absent                                 | 219           | 10                | 1.0          | 0.241   | 1.0          | -       |
| Present                                | 8             | 1                 | 3.43 (0.44-26.80) | -       | -            | -       |
| HIR criteria†                          |               |                   |              | 0.013   | 0.180        |         |
| No                                     | 218           | 9                 | 1.0          | -       | -            | -       |
| Yes                                    | 9             | 2                 | 6.96 (1.50-32.32) | 4.90 (0.48-49.99) |

FIGO, International Federation of Gynecology and Obstetrics; HIR, high intermediate risk; HR, hazard ratio; LVSI, lymphovascular space invasion; PLN, pelvic lymph node.

*According to MRC ASTEC trial [6]. †HIR criteria from a Gynecologic Oncology Group (GOG) trial-99 [12]. Women in the HIR group were (1) patients with moderate or poorly differentiated tumors with LVSI and invasion into the outer third of the myometrium, or (2) were over 50 years of age with any two of the above risk factors, or (3) over 70 years of age with any one risk factor above.
In this study, we classified nine patients into HIR group (according to the GOG 99 study [12]) for subgroup analyses. These patients experienced significantly high recurrence rate compared to those without HIR criteria (22.2% vs. 4.1%, HR, 6.9; 95% CI, 1.5 to 32.3; p=0.013). The most common pattern of recurrence in this study was vaginal recurrence, which is in concordance with other studies, although there are some pelvic and extra-pelvic recurrences [10-13,18]. Recent data from Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC-2) study showed equivalent benefits in vaginal control, DFS, and OS in the HIR patients between adjuvant vaginal brachytherapy and pelvic external beam radiation therapy (EBRT). Importantly, grade 1-2 gastrointestinal toxicities were lower with vaginal brachytherapy compared to pelvic EBRT (12.6% vs. 53.8%) [26]. Therefore, we suggest that PORT, meaning vaginal brachytherapy, should be given to patients with either stage IB grade 2 or HIR (GOG 99 criteria [12]) after surgery in order to achieve good locoregional control [27]. Due to small number of patients with FIGO 1988 stage IC, the statistical significance of this group of patients could not be tested.

FIGO staging has been revised since 2009 [28]. The FIGO 2009 staging system was validated by various studies for its clinical relevance for risk stratification [29-32]. Most studies showed that FIGO 2009 has improved prediction of prognosis. Likewise, our study confirmed that there was no difference in recurrence rate between FIGO 1988 stage IA and IB.

Recently, there were several studies which developed nomograms to predict the locoregional and distant controls in early stage endometrial cancer. Age, stage of disease, depth of myometrial invasion, histologic subtype, grade, lymph node status, and vascular invasion were factors used to create those nomograms [33,34]. In the future, molecular biological genetic markers such as L1 cell adhesion molecule (L1CAM), TP-53 mutation, DNA polymerase ε (POLE) mutation, and microsatellite instability will play significant role to determine patients’ prognoses in addition to current prognostic factors [35].

Nonetheless, our study demonstrated good outcome with salvage radiation therapy with a median OS of 53.3 months. There are evidences from the literature that salvage treatment, combining pelvic EBRT and vaginal brachytherapy, can successfully treat isolated vaginal recurrence with 5-year survival rate ranging from 50% to 60% [36-38].

There are several weaknesses in our study, including a retrospective manner, lack of some follow-up data, and routine surveillance without CT/MRI imaging unless clinically indicated and relatively small sample size. However, this is the first report of stage I endometrial cancer treated with surgery alone in our institute and Thailand. These results represent our practice and treatment outcomes showing some subgroup of patients do require adjuvant treatment rather than surgery alone.

In conclusion, low risk endometrial cancer patients had excellent outcomes with surgery alone. Our study showed that no single factor was demonstrated to be an independent predictor for recurrence. Specific group of patients whose pathology revealed moderately differentiated endometrioid carcinoma with myometrial invasion should receive adjuvant treatment rather than surgery alone.
ACKNOWLEDGMENTS

We would like to thank Ms. Wipa Paholpak for patients’ information providing, and Mr. Suthipol Udompunthurak (Siriraj Medical Research Center) for statistical analyses.

REFERENCES

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81. PUBMED | CROSSREF

2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29. PUBLMED | CROSSREF

3. Moore MA, Attasara P, Khuhaprema T, Le TN, Nguyen TH, Raingsey PP, et al. Cancer epidemiology in mainland South-East Asia - past, present and future. Asian Pac J Cancer Prev 2010;11 Suppl 2:67-80. PUBMED

4. Khuhaprema T, Attasara P, Sriplung H, Wiangnon S, Sangrajrang S. Cancer incidence in Thailand: Corpus uteri. Cancer in Thailand. Bangkok: Ministry of Public Health; 2013. p. 54.

5. Benedet JL, Bender H, Jones H 3rd, Nqan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-62. PUBMED | CROSSREF

6. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125-36. PUBMED | CROSSREF

7. Benedetti Panici P, Basile S, Maneschi F, Alberto Liissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-16. PUBMED | CROSSREF

8. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2010;(1):CD007585.

9. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65. PUBMED | CROSSREF

10. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419-27. PUBMED

11. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jodsen JJ, Wårlåm-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage I endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-11. PUBMED | CROSSREF

12. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744-51. PUBMED | CROSSREF

13. ASTEC/EN.5 Study Group; Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373:137-46. PUBMED | CROSSREF

14. Chi DS, Barakat RR, Palayekar MJ, Levine DA, Sonoda Y, Aletiari K, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer 2008;18:269-73. PUBMED | CROSSREF
15. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst 2012;104:1625-34.

16. Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 2000;182:1506-19.

17. Zaino RJ, Kurman RJ, Diana KL, Morrow CP. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 1995;75:81-6.

18. Rasool N, Fader AN, Seamon L, Neubauer NL, Shahin FA, Alexander HA, et al. Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol 2010;116:10-4.

19. Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2015;9:CD007585.

20. Setakornnukul J, Petsuksiri J, Wanglikitkoon S, Warnnisorn M, Thephamongkhol K, Chansip Y, et al. Long term outcomes of patients with endometrial carcinoma treated with radiation - Siriraj Hospital experience. Asian Pac J Cancer Prev 2014;15:2279-85.

21. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, et al. NCCN clinical practice guidelines: uterine neoplasms 2015 [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2015. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp

22. Creutzberg CL, Nout RA. The role of radiotherapy in endometrial cancer: current evidence and trends. Curr Oncol Rep 2011;13:472-8.

23. Lukka H, Chambers A, Fyles A, Thephamongkhol K, Fung-Kee-Fung M, Elit L, et al. Adjuvant radiotherapy in women with stage I endometrial cancer: a systematic review. Gynecol Oncol 2006;102:361-8.

24. Koh WJ, Tran AB, Douglas JG, Stelzer KJ. Radiation therapy in endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2001;15:417-32.

25. Creutzberg CL, Nout RA, Lybeert ML, Wârlâm-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e631-8.

26. Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816-23.

27. Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, et al. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2014;4:137-44.

28. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103-4.

29. Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Khunnarong J, Pataraadool K, Thavaramara T. Endometrial carcinoma: clinical characteristic and survival rates by the new compared to the prior FIGO staging systems. J Med Assoc Thai 2013;96:505-12.

30. Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, et al. Comparative performance of the 2009 International Federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol 2010;116:1141-9.

31. Werner HM, Trovik J, Marcikiewicz J, Tinglestad S, Staff AC, Amant F, et al. Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecol Oncol 2012;125:103-8.
32. Cooke EW, Pappas L, Gaffney DK. Does the revised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes? Cancer 2011;117:4231-7.

33. Creutzberg CL, van Stiphout RG, Nout RA, Lutgens LC, Jürgenliemk-Schulz IM, Jobsen JJ, et al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys 2015;91:530-9.

34. Abu-Rustum NR, Zhou Q, Gomez JD, Alektiar KM, Hensley ML, Soslow RA, et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol 2010;116:399-403.

35. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet 2016;387:1094-108.

36. Huh WK, Straughn JM Jr, Mariani A, Podratz KC, Havrilesky LJ, Alvarez-Secord A, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer 2007;17:886-9.

37. Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys 2003;56:1366-72.

38. Lin LL, Grigsby PW, Powell MA, Mutch DG. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. Int J Radiat Oncol Biol Phys 2005;63:500-4.